425 related articles for article (PubMed ID: 25222039)
1. Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals.
Mormino EC; Betensky RA; Hedden T; Schultz AP; Amariglio RE; Rentz DM; Johnson KA; Sperling RA
JAMA Neurol; 2014 Nov; 71(11):1379-85. PubMed ID: 25222039
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals.
Mormino EC; Papp KV; Rentz DM; Schultz AP; LaPoint M; Amariglio R; Hanseeuw B; Marshall GA; Hedden T; Johnson KA; Sperling RA
JAMA Neurol; 2016 Oct; 73(10):1185-1191. PubMed ID: 27548655
[TBL] [Abstract][Full Text] [Related]
3. Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia.
Zhao Y; Tudorascu DL; Lopez OL; Cohen AD; Mathis CA; Aizenstein HJ; Price JC; Kuller LH; Kamboh MI; DeKosky ST; Klunk WE; Snitz BE
JAMA Neurol; 2018 Jan; 75(1):88-96. PubMed ID: 29114732
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology.
Gordon BA; Blazey T; Su Y; Fagan AM; Holtzman DM; Morris JC; Benzinger TL
JAMA Neurol; 2016 Oct; 73(10):1192-1200. PubMed ID: 27548756
[TBL] [Abstract][Full Text] [Related]
5. Subjective cognitive concerns, amyloid-β, and neurodegeneration in clinically normal elderly.
Amariglio RE; Mormino EC; Pietras AC; Marshall GA; Vannini P; Johnson KA; Sperling RA; Rentz DM
Neurology; 2015 Jul; 85(1):56-62. PubMed ID: 26048028
[TBL] [Abstract][Full Text] [Related]
6. Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study.
Rabin JS; Schultz AP; Hedden T; Viswanathan A; Marshall GA; Kilpatrick E; Klein H; Buckley RF; Yang HS; Properzi M; Rao V; Kirn DR; Papp KV; Rentz DM; Johnson KA; Sperling RA; Chhatwal JP
JAMA Neurol; 2018 Sep; 75(9):1124-1131. PubMed ID: 29799986
[TBL] [Abstract][Full Text] [Related]
7. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.
Mormino EC; Betensky RA; Hedden T; Schultz AP; Ward A; Huijbers W; Rentz DM; Johnson KA; Sperling RA; ; ;
Neurology; 2014 May; 82(20):1760-7. PubMed ID: 24748674
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
[TBL] [Abstract][Full Text] [Related]
9. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.
Donohue MC; Sperling RA; Salmon DP; Rentz DM; Raman R; Thomas RG; Weiner M; Aisen PS; ; ;
JAMA Neurol; 2014 Aug; 71(8):961-70. PubMed ID: 24886908
[TBL] [Abstract][Full Text] [Related]
10. Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.
Winer JR; Maass A; Pressman P; Stiver J; Schonhaut DR; Baker SL; Kramer J; Rabinovici GD; Jagust WJ
JAMA Neurol; 2018 Feb; 75(2):227-235. PubMed ID: 29228071
[TBL] [Abstract][Full Text] [Related]
11. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.
Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS;
JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267
[TBL] [Abstract][Full Text] [Related]
12. Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study.
Pietrzak RH; Lim YY; Neumeister A; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Restrepo C; Martins RN; Masters CL; Villemagne VL; Rowe CC; Maruff P;
JAMA Psychiatry; 2015 Mar; 72(3):284-91. PubMed ID: 25629787
[TBL] [Abstract][Full Text] [Related]
13. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
[TBL] [Abstract][Full Text] [Related]
14. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
[TBL] [Abstract][Full Text] [Related]
15. Associations of Physical Activity and β-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults.
Rabin JS; Klein H; Kirn DR; Schultz AP; Yang HS; Hampton O; Jiang S; Buckley RF; Viswanathan A; Hedden T; Pruzin J; Yau WW; Guzmán-Vélez E; Quiroz YT; Properzi M; Marshall GA; Rentz DM; Johnson KA; Sperling RA; Chhatwal JP
JAMA Neurol; 2019 Oct; 76(10):1203-1210. PubMed ID: 31312836
[TBL] [Abstract][Full Text] [Related]
16. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
[TBL] [Abstract][Full Text] [Related]
17. Association of β-Amyloid Burden With Sleep Dysfunction and Cognitive Impairment in Elderly Individuals With Cognitive Disorders.
You JC; Jones E; Cross DE; Lyon AC; Kang H; Newberg AB; Lippa CF
JAMA Netw Open; 2019 Oct; 2(10):e1913383. PubMed ID: 31617927
[TBL] [Abstract][Full Text] [Related]
18. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.
Sperling RA; Donohue MC; Raman R; Sun CK; Yaari R; Holdridge K; Siemers E; Johnson KA; Aisen PS;
JAMA Neurol; 2020 Jun; 77(6):735-745. PubMed ID: 32250387
[TBL] [Abstract][Full Text] [Related]
19. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people.
Wirth M; Villeneuve S; Haase CM; Madison CM; Oh H; Landau SM; Rabinovici GD; Jagust WJ
JAMA Neurol; 2013 Dec; 70(12):1512-9. PubMed ID: 24166579
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
